Madalyn Neff

About Madalyn Neff

This author has not yet filled in any details.
So far Madalyn Neff has created 54 blog entries.

[Blog Post] COVID-19 and Mental Health Care: A Double Disparity

From a mental health perspective, the COVID-19 pandemic is a perfect storm. Fear of catching and spreading the novel coronavirus, economic-related anxiety, and the isolation from sheltering at home are taking an enormous emotional toll.

That’s especially true in minority communities, which face double jeopardy. They are more likely to be affected by COVID-19 and less […]

2020-05-18T16:58:26-04:00May 18, 2020|General|

[ACRP Journal Article] Clinical Research Professionals Have an Important Role to Play

Article published in the Journal of the Association of Clinical Research Professionals 

Written by Executive Director Marjorie A. Speers, Ph.D.

As a clinical research professional, most of your interactions with patients are related to their involvement in clinical trials: recruiting, assessing, and enrolling participants; obtaining informed consent; administering trial procedures; and monitoring patient responses to the investigational […]

2020-05-14T14:28:53-04:00May 14, 2020|General|

[Blog Post] Making Sure #VaccinesWork for All

Friday, April 24, is the first day of World Immunization Week, an annual global effort to promote the importance of preventing disease—and saving lives—by improving vaccination rates. Always an important message, it is especially compelling this year as the world grapples with the COVID-19 pandemic.

The same is true for this year’s World Immunization Week theme, […]

2020-04-23T10:20:40-04:00April 20, 2020|General|

[Guest Post] Patient Involvement Improves Clinical Trial Design

A blog post by Anne B. Cropp, Pharm.D., BCAP, Clinical Research Pathways Board of Directors

Many clinical trials fail in part because they can’t recruit or retain enough patients to accurately assess an investigational drug’s safety and effectiveness. That’s especially true for trials that involve patients with ultrarare diseases, which FDA defines […]

2020-03-23T17:06:06-04:00March 23, 2020|General|

[Blog Post] The Need to Engage Minorities in MS research

Multiple sclerosis (MS) is an unpredictable, potentially disabling disease of the central nervous system. Although it has long been viewed as a disease of white women of northern European ancestry, MS also affects black, Latino, and Hispanic Americans.  

In fact, recent data suggest MS might be more common among […]

2020-03-09T19:52:59-04:00March 9, 2020|General|

[Blog Post] Tackling One of the Most Preventable Cancers

January is Cervical Health Awareness Month, an ideal time to call attention to one of the most preventable cancers.

The good news is that cervical cancer rates have declined significantly because of widespread use of the Pap screening test. Even better, cervical cancer can now be prevented by a vaccine that targets HPV, the virus that […]

2020-03-03T12:19:57-05:00February 17, 2020|General|

[Blog Post] Tackling the Costs that Can Impede Expanded Access

A blog post by Clinical Research Pathways Executive Director Marjorie A. Speers, Ph.D.

A streamlined Food and Drug Administration (FDA) expanded access process has made it easier for desperately ill patients to try experimental drugs, biologics, and medical devices. Despite this progress, costs—to patients, healthcare providers, and product developers—present significant barriers to participation.

As a result, […]

2020-02-03T16:35:17-05:00February 3, 2020|General|

[Blog Post] Transparency Informs Diversity Efforts

In response to increased public interest, the Food and Drug Administration (FDA) provides data on the demographic makeup of clinical trials for recently approved drugs. In 2018, for example, FDA approved 59 new drugs based on the results of clinical trials involving nearly 44,000 participants. Of those, 69% were white and 56% were women. In […]

2020-01-20T16:39:56-05:00January 20, 2020|General|
Load More Posts